ArticlemedRxiv : the preprint server for health sciences2026
Ten-Year Risk of Primary Malignant Brain Tumors After Buprenorphine vs Naltrexone Exposure: A Retrospective Cohort Study Using the Epic Cosmos Database.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Short-term neurobiological effects of opioids are well characterized, yet the long-term consequences of substance exposure on malignancy risk remain poorly understood. Ethical constraints limit prospective analysis of opioid exposure and primary malignant brain tumor (PMBT) risk in human patients, making large-scale electronic health record (EHR) analyses essential. This study evaluates the 10-year incidence of PMBTs among adults with opioid-abuse disorder related diagnoses exposed to either buprenorphine or naltrexone. Methods: We conducted a retrospective cohort study using the Epic Cosmos EHR database. Cohorts were defined by exclusive exposure to buprenorphine or naltrexone, with a non-exposed comparator cohort. PMBT incidence within 1-120 months post-exposure was identified. Due to platform constraints, multivariable regression could not be performed; instead, confounding was addressed using Mantel-Haenszel stratification across age, sex, and race. Results: There was no significant difference in 10-year PMBT incidence between patients exposed exclusively to buprenorphine versus naltrexone (Mantel-Haenszel OR = 1.028, 95% CI 0.968-1.092; p = 0.381), however PMBT risk was lower for opioid disorder patients receiving either drug than for the control group. Sex-specific analyses suggested women exposed to naltrexone had significantly lower PMBT incidence relative to buprenorphine exposure (OR = 0.783, 95% CI 0.617-0.994; p = 0.044), whereas men showed a non-significant increase (OR = 1.211, 95% CI 0.939-1.564; p = 0.139). Conclusions: Buprenorphine and naltrexone were associated with comparable overall 10-year PMBT risk among adults with opioid-related diagnoses. The sex-specific interaction suggests naltrexone may be associated with reduced PMBT incidence in women, warranting further investigation. These findings contribute to the long-term neuro-oncologic safety profiles of opioid use disorder treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.